Difference between revisions of "Necitumumab (Portrazza)"
m (PeterYang moved page Necitumumab (IMC-11F8) to Necitumumab (Portrazza)) |
(FDA approval) |
||
| Line 1: | Line 1: | ||
| − | = | + | ==General information== |
| − | + | Class/mechanism: Recombinant human IgG1 EGFR monoclonal antibody. Necitumumab binds to the human epidermal growth factor receptor (EGFR) prevents it from binding to its ligands. This interferes with EGFR's effects on growth of malignant cells, angiogenesis, and inhibition of apoptosis. In vitro, necitumumab has been observed to cause antibody-dependent cellular cytotoxicity (ADCC) in cells which express EGFR, induce the internalization of EGFR, and lead to its degradation.<ref name=insert>[http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125547s000lbl.pdf Necitumumab (Portrazza) package insert]</ref><ref>[[Media:Necitumumab.pdf|Necitumumab (Portrazza) package insert (locally hosted backup)]]</ref><ref>[http://portrazza.com/ Portrazza manufacturer's website]</ref> | |
| + | <br>Route: IV | ||
| + | <br>Extravasation: no information | ||
| + | |||
| + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | ||
| + | |||
| + | ==Diseases for which it is used== | ||
| + | *[[Non-small cell lung cancer]] | ||
| + | |||
| + | ==Patient drug information== | ||
| + | *Brief patient counseling information can be found in the [http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125547s000lbl.pdf Necitumumab (Portrazza) package insert]<ref name="insert"></ref> | ||
| + | |||
| + | ==History of changes in FDA indication== | ||
| + | *11/24/2015: [http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm474278.htm FDA approved] to be used "in combination with [[Gemcitabine (Gemzar)|gemcitabine]] and [[Cisplatin (Platinol)|cisplatin]], for first-line treatment of patients with metastatic squamous [[non-small cell lung cancer]].<ref name="insert"></ref> | ||
| + | |||
| + | ==Also known as== | ||
| + | IMC-11F8 | ||
| + | |||
| + | ==References== | ||
| + | <references/> | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
| Line 9: | Line 28: | ||
[[Category:Anti-EGFR antibodies]] | [[Category:Anti-EGFR antibodies]] | ||
| − | [[Category: | + | [[Category:Non-small cell lung cancer medications]] |
| + | [[Category:Drugs FDA approved in 2015]] | ||
Revision as of 04:43, 25 November 2015
General information
Class/mechanism: Recombinant human IgG1 EGFR monoclonal antibody. Necitumumab binds to the human epidermal growth factor receptor (EGFR) prevents it from binding to its ligands. This interferes with EGFR's effects on growth of malignant cells, angiogenesis, and inhibition of apoptosis. In vitro, necitumumab has been observed to cause antibody-dependent cellular cytotoxicity (ADCC) in cells which express EGFR, induce the internalization of EGFR, and lead to its degradation.[1][2][3]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Brief patient counseling information can be found in the Necitumumab (Portrazza) package insert[1]
History of changes in FDA indication
- 11/24/2015: FDA approved to be used "in combination with gemcitabine and cisplatin, for first-line treatment of patients with metastatic squamous non-small cell lung cancer.[1]
Also known as
IMC-11F8